Direct accesses

  • Go to main menu
  • Go to main content
Menu
GenSight GenSight
Search the site
  • Contact
  • Careers
  • You are viewing the website in English en
  • fr
Search the site
  • Whowe are
    • Company
    • Leadership
    • Collaborations
  • Diseaseswe target
    • Diseases we target
    • Leber Hereditary Optic Neuropathy (LHON)
    • Retinitis Pigmentosa (RP)
    • Geographic Atrophy in Dry-AMD
  • Ourtechnologies
    • Technologies we are applying
    • Gene Therapy
    • Mitochondrial Targeting Sequence (MTS)
    • Optogenetics
    • Clinical development Summary
  • Investors
    • Company Overview
    • Financial press releases
    • Events & presentations
    • Stock information & Financial agenda
    • Governance
    • Documentation
  • Media

Finance

10 March 2023

GenSight Biologics to Present at Upcoming Medical Conferences

07 March 2023

GenSight Biologics Provides Update on LUMEVOQ® Manufacturing and Commercialization Timelines

28 February 2023

GenSight Biologics Announces its 2023 Financial Calendar

06 February 2023

GenSight Biologics announces the drawdown of the first EUR 8 million tranche under its credit agreement with the European Investment Bank

26 January 2023

GenSight Biologics Reports Cash Position as of December 31, 2022, FY 2022 Revenues and Provides Business Update

23 December 2022

GenSight Biologics secures €12 Million financing through a premium convertible notes issuance to an institutional investor and provides business update

04 November 2022

GenSight Biologics secures a €35 million credit facility from the European Investment Bank to support the launch of LUMEVOQ® in Europe

28 October 2022

GenSight Biologics Reports Cash Position and Revenues as of September 30, 2022

20 September 2022

GenSight Biologics to Present at Upcoming Industry and Investor Conferences

28 July 2022

GenSight Biologics Reports Interim Financial Results for the First Half of 2022

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • …
  • 9
  • View next 9 articles
© 2023 Gensight Biologics
  • Terms of use
  • Sitemap
  • Contact
  • Credits
  • Cookies management
Go back to the page of the page